EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|June 1, 2001
Better awareness of airborne irritant problems is necessary
Hershey, Pa. - There is potential for growing problems from the use of triglycidyl isocyanurate, which is used as a hardener in thermosetting polyester powder coatings in products ranging from patio furniture to auto parts, said Bruce A. Brod, M.D., in an address at the American Contact Dermatitis Society gathering that highlighted state-of-the-art issues.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
3
Tulisokibart Meets Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial
4
Repigmentation With Upadacitinib Continues Through Week 76 in Non-Segmental Vitiligo
5